The glucose transporter PfHT1 is an antimalarial target of the HIV protease inhibitor lopinavir

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6203-6209

  Kraft, Thomas E ^a   Armstrong, Christopher ^a   Heitmeier, Monique R ^a   Odom, Audrey R ^a   Hruz, Paul W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER PFHT1; LOPINAVIR; MESSENGER RNA; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; HEXOSE TRANSPORTER 1 PROTEIN, PLASMODIUM FALCIPARUM; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDEMIC DISEASE; ENERGY RESOURCE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MORBIDITY; MORTALITY; NONHUMAN; PARASITE SURVIVAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG REPOSITIONING; ERYTHROCYTE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; IC50; METABOLISM; PARASITOLOGY; STRUCTURE ACTIVITY RELATION; TRANSPORT AT THE CELLULAR LEVEL;

ANTIMALARIALS; BIOLOGICAL TRANSPORT; DRUG REPOSITIONING; ERYTHROCYTES; GENE EXPRESSION; GLUCOSE; HEK293 CELLS; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LOPINAVIR; MONOSACCHARIDE TRANSPORT PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84942279501     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00899-15     Document Type: Article

References (43)

1. World Health Organization. 2014. World malaria report 2014, p 165-176. World Health Organization, Geneva, Switzerland.
2. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. 2012. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 367:2110-2118. http://dx.doi.org/10.1056/NEJMoa1200501.
3. Nsanzabana C, Rosenthal PJ. 2011. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother 55:5073-5077. http://dx.doi.org/10.1128/AAC.05130-11.
4. Hobbs CV, Voza T, Coppi A, Kirmse B, Marsh K, Borkowsky W, Sinnis P. 2009. HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis 199:134-141. http://dx.doi.org/10.1086/594369.
5. Hobbs CV, Neal J, Conteh S, Donnelly L, Chen J, Marsh K, Lambert L, Orr-Gonzalez S, Hinderer J, Healy S, Borkowsky W, Penzak SR, Chakravarty S, Hoffman SL, Duffy PE. 2014. HIV treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivo. PLoS One 9:e100138. http://dx.doi.org/10.1371/journal.pone.0100138.
6. Nalam MNL, Schiffer CA. 2008. New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS 3:642-646. http://dx.doi.org/10.1097/COH.0b013e3283136cee.
7. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. 2002. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci U S A 99:990-995. http://dx.doi.org/10.1073/pnas.022630099.
8. Boddey JA, Hodder AN, Günther S, Gilson PR, Patsiouras H, Kapp EA, Pearce JA, de Koning-Ward TF, Simpson RJ, Crabb BS, Cowman AF. 2010. An aspartyl protease directs malaria effector proteins to the host cell. Nature 463:627-631. http://dx.doi.org/10.1038/nature08728.
9. Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ. 2006. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob Agents Chemother 50:2207-2209. http://dx.doi.org/10.1128/AAC.00022-06.
10. Hobbs CV, Tanaka TQ, Muratova O, Van Vliet J, Borkowsky W, Williamson KC, Duffy PE. 2013. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis 208:139-148. http://dx.doi.org/10.1093/infdis/jit132.
11. Hresko RC, Hruz PW. 2011. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One 6:e25237. http://dx.doi.org/10.1371/journal.pone.0025237.
12. Murata H, Hruz PW, Mueckler M. 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254. http://dx.doi.org/10.1074/jbc.C000228200.
13. Murata H, Hruz PW, Mueckler M. 2002. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 16:859-863. http://dx.doi.org/10.1097/00002030-200204120-00005.
14. Slavic K, Krishna S, Derbyshire ET, Staines HM. 2011. Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa. Malar J 10:165. http://dx.doi.org/10.1186/1475-2875-10-165.
15. Woodrow CJ, Penny JI, Krishna S. 1999. Intraerythrocytic Plasmodium falciparum expresses a high affinity facilitative hexose transporter. J Biol Chem 274:7272-7277. http://dx.doi.org/10.1074/jbc.274.11.7272.
16. Kirk K. 2001. Membrane transport in the malaria-infected erythrocyte. Physiol Rev 81:495-537.
17. Mehta M, Sonawat HM, Sharma S. 2006. Glycolysis in Plasmodium falciparum results in modulation of host enzyme activities. J Vector Borne Dis 43:95-103.
18. Blume M, Hliscs M, Rodriguez-Contreras D, Sanchez M, Landfear S, Lucius R, Matuschewski K, Gupta N. 2011. A constitutive pan-hexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs. FASEB J 25:1218-1229. http://dx.doi.org/10.1096/fj.10-173278.
19. Joet T, Eckstein-Ludwig U, Morin C, Krishna S. 2003. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc Natl Acad Sci U S A 100:7476-7479. http://dx.doi.org/10.1073/pnas.1330865100.
20. Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, Odom AR. 2011. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 50:3570-3577. http://dx.doi.org/10.1021/bi200113y.
21. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675. http://dx.doi.org/10.1126/science.781840.
22. Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL, Coley PD, Kursar TA, Romero LI, Ortega-Barria E. 2004. A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg 70:119-124.
23. Chaudhary S, Pak JE, Gruswitz F, Sharma V, Stroud RM. 2012. Overexpressing human membrane proteins in stably transfected and clonal human embryonic kidney 293S cells. Nat Protoc 7:453-466. http://dx.doi.org/10.1038/nprot.2011.453.
24. Aerni-Flessner L, Abi-Jaoude M, Koenig A, Payne M, Hruz PW. 2012. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol 11:63. http://dx.doi.org/10.1186/1475-2840-11-63.
25. Saliba KJ, Krishna S, Kirk K. 2004. Inhibition of hexose transport and abrogation of pH homeostasis in the intraerythrocytic malaria parasite by an O-3-hexose derivative. FEBS Lett 570:93-96. http://dx.doi.org/10.1016/j.febslet.2004.06.032.
26. Hresko RC, Kraft TE, Tzekov A, Wildman SA, Hruz PW. 2014. Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding. J Biol Chem 289:16100-16113. http://dx.doi.org/10.1074/jbc.M113.528430.
27. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9:40. http://dx.doi.org/10.1186/1471-2105-9-40.
28. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725-738. http://dx.doi.org/10.1038/nprot.2010.5.
29. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2015. The I-TASSER Suite: protein structure and function prediction. Nat Methods 12:7-8. http://dx.doi.org/10.1038/nmeth.3213.
30. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461. http://dx.doi.org/10.1002/jcc.21334.
31. Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T, De Groot R, Burger DM. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J Acquir Immune Defic Syndr 39:63-68. http://dx.doi.org/10.1097/01.qai.0000155203.89350.85.
32. Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C. 2006. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother 57:1168-1171. http://dx.doi.org/10.1093/jac/dkl136.
33. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. 2010. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 54:381-388. http://dx.doi.org/10.1097/QAI.0b013e3181d6c9ed.
34. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White A, Benson CC, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9. http://dx.doi.org/10.1097/00002030-200101050-00002.
35. Slavic K, Straschil U, Reininger L, Doerig C, Morin C, Tewari R, Krishna S. 2010. Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality. Mol Microbiol 75:1402-1413. http://dx.doi.org/10.1111/j.1365-2958.2010.07060.x.
36. Chandwani A, Shuter J. 2008. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023-1033.
37. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K. 2008. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 118:e20-e28. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.189623.
38. Hruz PW, Murata H, Qiu H, Mueckler M. 2002. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51:937-942. http://dx.doi.org/10.2337/diabetes.51.4.937.
39. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. 2001. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:F11-F18. http://dx.doi.org/10.1097/00002030-200105040-00001.
40. Noor MA, Flint OP, Maa J-F, Parker RA. 2006. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20:1813-1821. http://dx.doi.org/10.1097/01.aids.0000244200.11006.55.
41. Ortiz D, Guiguemde WA, Johnson A, Elya C, Anderson J, Clark J, Connelly M, Yang L, Min J, Sato Y, Guy RK, Landfear SM. 2015. Identification of selective inhibitors of the Plasmodium falciparum hexose transporter PfHT by screening focused libraries of anti-malarial compounds. PLoS One 10:e0123598. http://dx.doi.org/10.1371/journal.pone.0123598.
42. Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, Yan N. 2014. Crystal structure of the human glucose transporter GLUT1. Nature 510:121-125. http://dx.doi.org/10.1038/nature13306.
43. Slavic K, Delves MJ, Prudêncio M, Talman AM, Straschil U, Derbyshire ET, Xu Z, Sinden RE, Mota MM, Morin C, Tewari R, Krishna S, Staines HM. 2011. Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite's life cycle. Antimicrob Agents Chemother 55:2824-2830. http://dx.doi.org/10.1128/AAC.01739-10.